Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
79 hedge funds and large institutions have $32.9M invested in Surface Oncology, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 14 closing their positions.
1,275% more call options, than puts
Call options by funds: $165K | Put options by funds: $12K
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 84 → 79 (-5)
32% less capital invested
Capital invested by funds: $48.6M → $32.9M (-$15.7M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$1.76M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$1.76M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$916K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$812K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$764K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.16M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$685K |
| 3 |
Millennium Management
New York
|
-$523K |
| 4 |
E
Ergoteles
New York
|
-$226K |
| 5 |
SIM
SummerHaven Investment Management
Stamford,
Connecticut
|
-$220K |
SURF Hedge Fund Activity: Q3 2022 in Review
79 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q3 2022, worth a combined $32.9M — down 32% from $48.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SURF and 9 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 26 added.
The largest buyer was Nikko Asset Management Americas, opening a new position worth an estimated $1.76M. The largest seller was EcoR1 Capital, cutting an estimated $1.16M.
- 79 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q3 2022, down from 84 in Q2 2022.
- Funds reported $32.9M of Surface Oncology, Inc. Common Stock stock for Q3 2022, down 32% quarter-over-quarter.
- 9 funds opened new Surface Oncology, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -5 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q3 2022 was Nikko Asset Management Americas, an estimated $1.76M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q3 2022 was EcoR1 Capital, an estimated $1.16M sold.
Based on aggregated 13F filings for Q3 2022.